Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, NovartisInvestors Business Daily • 01/07/24
Novartis (NVS) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 01/06/24
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in IndianapolisGlobeNewsWire • 01/05/24
MDMA therapy company Lykos raises $100M in Series A funding as it eyes FDA approvalMarket Watch • 01/05/24
Novartis (NVS) Increases Despite Market Slip: Here's What You Need to KnowZacks Investment Research • 01/03/24
Voyager Therapeutics' Novartis deal has analysts bullish on stock's long-term outlookProactive Investors • 01/02/24
Voyager Therapeutics and Novartis Sign Deal for Neurological Disease TreatmentsInvestopedia • 01/02/24
Novartis Sweetens Its Deal With Voyager, And Voyager Stock — Up 25% — Flashes A Bullish SignInvestors Business Daily • 01/02/24
Voyager Therapeutics shares pop on collaboration with Novartis worth up to $1.2BProactive Investors • 01/02/24
Voyager Therapeutics shares soar 32% on news of deal with Novartis that includes up to $1.2 billion in milestone paymentsMarket Watch • 01/02/24
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene TherapiesGlobeNewsWire • 01/02/24
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)GlobeNewsWire • 12/11/23
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)PRNewsWire • 12/11/23
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissionsGlobeNewsWire • 12/08/23
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNHPRNewsWire • 12/06/23